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The standard primary treatment for advanced prostate cancer has been hormonal therapy since the
1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after
a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has
been regarded as the standard treatment. However, survival advantages of docetaxel over other treat-
ments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone,
enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC,
and more such agents based on diverse mechanisms are under investigation or evaluation. In this article,
the authors reviewed the current literature on recent advances in medical treatment of prostate cancer,
especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently un-
dergoing investigation and their mechanisms.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is the fourth most frequent cancer in general
and the second most common cancer in men. About 1.1 million
cases of prostate cancer were diagnosed worldwide in 2012, ac-
counting for 15% of all cancers in men.1 The incidence of prostate
cancer varies by > 25-fold. The incidence is high in Australia, New
Zealand, North America, and Europe (age standardized rate:
85e112), but it remains low in Eastern and South Central Asia (age
standardized rate: 4.5e10.5). In addition, prostate cancer is the ﬁfth
leading cause of death from cancer in men, with an estimated
307,000 deaths representing 6.6% of total male cancer mortality.
There is a relatively smaller variation in mortality than in the
incidenceworldwide. Mortality rates are generally high in people of
African descent (Caribbean, Sub-Saharan Africa: 19e24 deaths/
100,000 persons), intermediate in the Americas and Oceania, and
very low in South Central Asia (2.9 deaths/100,000 persons).
However, the proportion of metastatic prostate cancer is higher in
Asian countries than in Western countries.Asan Medical Center, 388-1
rea.
ciﬁc Prostate Society, Published bThe initial treatment of choice for metastatic prostate cancer is
medical or surgical castration. However, metastatic prostate cancer
generally acquires resistance to androgen deprivation therapy
(ADT) after a median duration of 18 months. The presumed
mechanisms of resistance to ADT include persistence of intra-
tumoral androgen despite castration levels of serum testosterone,
increased androgen receptor (AR) protein expression, mutated
forms of active AR protein (AR splice variants or AR point muta-
tion), increased activity of AR coregulatory proteins (Src family of
proteins), and overactive signaling of other proliferative pathways
[mammalian target of rapamycin (mTOR) and retinoblastoma
protein pathway].2e12
Currently, metastatic castration-resistant prostate cancer
(CRPC) is usually treated with chemotherapy (docetaxel, mitixan-
trone, and cabazitaxel) or secondary hormonal therapeutic agents
such as abiraterone or enzalutamide. Immunotherapy with
sipuleucel-T has been employed in treating asymptomatic or
minimally metastatic CRPC without visceral metastasis. Bone
metastasis is managed with zoledronic acid, denosumab, or
radium-223. Radium-223 is used for symptomatic bone metastasis
without visceral metastasis. However, the effects of these treat-
ments are less than satisfactory, and the need for novel agents in
treating metastatic CRPC is still present.
A considerable number of novel agents against metastatic CRPC
based on diverse mechanisms are currently under investigation
worldwide. In this article, the authors summarized ongoing clinicaly Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 4 (2016) 37e4238trials for novel drugs in prostate cancer. In addition, the authors
reviewed the current literature and elaborated on novel drugs
currently undergoing investigation according to their mechanisms
of action, including androgen pathway targeted therapy, cytotoxic
chemotherapy, target agents and vaccines, immunotherapy, and
gene-based therapy.2. Ongoing clinical trials for drugs on prostate cancer
Owing to the high incidence of prostate cancer, various novel
drugs are currently being investigated. The authors listed those
currently undergoing Phase II or III clinical trials for prostate cancer,
especially metastatic CRPC, in Table 1. As of now, > 30 agents are
under clinical evaluation, with some of these in Phase III clinical
trials.3. Androgen pathway targeted therapy
One well-known mechanism responsible for acquisition of
castration resistance is activation of AR by alternative androgens.
CRPC may bypass testosterone-mediated modulation using the 5a-
androstanedione pathway, which is regarded as a predominant
pathway. Moreover, the 17,20-lyase activity of cytochrome P450 17
(CYP17), in addition to 3b-hydroxysteroid dehydrogenase and 5a-
reductase activity, may form alternative pathways from a choles-
terol precursor. CYP17 is regarded as a potent therapeutic target in
treating metastatic CRPC. In addition, AR ampliﬁcation is demon-
strated in ~30% of CRPC, and increased expression of AR mRNA has
been suggested as a mechanism associated with decreasedTable 1 Ongoing clinical trials for novel agents in prostate cancer.
Drug Registry number Completion Enroll Ph
TAK-700 (orteronel) NCT01707966 Jul 2020 1,486 I
VT-464 NCT02012920 Aug 2016 141 I
JNJ-56021927 (apamutamide) NCT01171898 Oct 2026 1,500 I
BAY1841788 (ODM-201) NCT02200614 Jun 2020 1,500 I
MLN8237 (alisertib) NCT01799278 Feb 2017 60 I
PROSTVAC NCT02649855 Jan 2020 38 I
Ipilimumab NCT01688492 Sep 2016 57 I
EPI-506 NCT02606123 Dec 2017 166 I
DCVAC NCT02111577 Jun 2018 1,170 I
AZD5363 NCT02525068 Jun 2018 136 I
Alisertib NCT01848067 May 2018 43 I
OGX-011 (custirsen sodium) NCT01578655 Dec 2016 630 I
177Lu-J591 NCT00859781 Dec 2018 140 I
Olaparib NCT01682772 Dec 2016 89 I
AMG386 NCT01553188 Feb 2017 23 I
Galeterone NCT01709734 Aug 2017 144 I
KPT-330 (selinexor) NCT02215161 Jun 2018 54 I
MK-3475 (pembrolizamab) NCT02312557 Jan 2017 28 I
GX301 NCT02293707 Nov 2018 120 I
Everolimus NCT00976755 Dec 2017 37 I
TKI258 (dovitinib) NCT01741116 Jun 2016 44 I
Onapristone NCT02049190 Dec 2017 75 I
ODM-204 NCT02344017 May 2017 75 I
Carﬁlzomib NCT02047253 Apr 2018 28 I
Reolysin NCT01619813 Dec 2016 85 I
CYT107 NCT01881867 Jan 2017 80 I
Indoximod NCT01560923 Apr 2017 50 I
SHR3680 NCT02691975 Jun 2020 140 I
LY3023414 NCT02407054 May 2018 144 I
LEE011 (ribociclib) NCT02494921 Dec 2018 47 I
BKM120 NCT01385293 Dec 2016 66 I
LY2157299 NCT02452008 Jul 2019 60 I
ADT, androgen deprivation therapy; Enz, enzalutamide.hormone sensitivity in addition to enhanced intracellular conver-
sion of androgens to dihydrotestosterone. Although second-
generation AR antagonists have been approved for clinical usage,
the need for more potent AR antagonists remains. In this section,
the authors will brieﬂy summarize several investigational drugs,
including CYP17 inhibitors and AR inhibitors.3.1. CYP17 inhibitors
TAK-700 (orteronel; Takeda Pharmaceutical Company, Osaka,
Japan) is a CYP17 inhibitor with greater afﬁnity for 17,20-lyase
over 17-hydroxylase. In a recent Phase III trial involving pa-
tients with post- and pre-docetaxel CRPC, TAK-700 was shown to
offer an advantage in terms of radiographic progression-free
survival (PFS) without safety concerns, but it did not meet the
primary end point of improved overall survival.13 Takeda Phar-
maceutical Company (Osaka, Japan) recently decided to terminate
the development of orteronel. However, a Phase III trial
(NCT01809691) comparing ADT þ TAK-700 versus
ADT þ bicalutamide by Southwest Oncology Group is currently
recruiting metastatic prostate cancer patients.
VT-464 (viamet) is a novel oral CYP17 inhibitor with greater
afﬁnity for 17,20-lyase over 17-hydroxylase, which does not require
concomitant steroid administration. In preclinical studies, VT-464
showed superior selective suppression of androgen synthesis and
AR antagonism compared with abiraterone.14 VT-464 is currently
under Phase I and II clinical trials (NCT02012920).
Galeterone (VN/124-1, TOK-001; Tokai, Boston, Massachusetts,
United States) is an oral, semisynthetic, steroidal agent thatase Status Patient group
II Recruiting ADT þ TAK-700 vs. ADT þ bicalutamide
, II Recruiting Treatment-naïve vs. previous abiraterone & Enz
II Recruiting JNJ-56021927 vs. bicalutamide
II Recruiting BAY1841788 vs. placebo
I Not recruiting Neuroendocrine prostate cancer
I Recruiting Simultaneous vs. sequential docetaxel þ prostvac
, II Not recruiting Ipilimumab þ abiraterone
, II Recruiting EPI-506
II Recruiting DCVAC þ chemotherapy vs. placebo þ chemotherapy
I Recruiting AZD5363 þ Enz
, II Recruiting Alisertib þ abiraterone
II Not recruiting Custirsen þ cabazitaxel vs. cabazitaxel
I Recruiting 177Lu-J591 þ Keto vs. 111ln-J591þKeto
I Recruiting Olaparib
I Not recruiting Abiraterone þ AMG386 vs. abiraterone
I Recruiting Galeterone
I Recruiting KPT-330
I Recruiting Pembrolizamab þ enzalutamide
I Recruiting GX301
I Not recruiting Everolimus
I Recruiting TKI258
, II Recruiting Onapristone
, II Recruiting ODM-204
I Recruiting Carﬁlzomib
I Not recruiting Docetaxel þ reolysin vs. docetaxel
I Recruiting CYT107 vs. no therapy
I Recruiting Indoximod vs. placebo
, II Recruiting SHR3680
I Recruiting LY3023414 þ Enz vs. placebo þ Enz
, II Recruiting Docetaxel þ ribociclib
I Not recruiting BKM120
I Recruiting LY2157299 þ Enz vs. Enz
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inhibition and AR modulation. Galeterone is the most potent
CYP17 inhibitor to date that also has activity against 17-lyase. The
ARMOR2 clinical trial (NCT 01709734), an open label, two-part
Phase II trial, evaluated the safety and efﬁcacy of optimized
galeterone treatment in CRPC patients. Metastatic and non-
metastatic treatment-naïve CRPC patients were enrolled and
treated with daily oral doses of 1,700 mg, 2,550 mg, or 3,400 mg.
Abiraterone-refractory patients were allowed in this study. Pre-
liminary data showed that galeterone was well tolerated at doses
up to 3,400 mg daily. Prostate speciﬁc antigen (PSA) responses
were observed in treatment-naïve metastatic CRPC patients
treated at 2,550 mg daily, with 90% and 81% of patients achieving
a PSA decline of > 30% and 50%, respectively. Biochemical activity
and stable disease have been observed in abiraterone-refractory
patients, supporting the possibility of a different response pro-
ﬁle for galeterone compared with other second-generation
antihormonals.15
ASP9521 (Astellas, Tokyo, Japan) is the ﬁrst orally available 17b-
hydroxysteroid dehydrogenase inhibitor. It is presumed not to
interfere with glucocorticoid synthesis by bypassing the need for
prednisone. In a ﬁrst-in-human Phase I and II study, ASP9521
evoked no biochemical or radiological response in 13 post-
chemotherapy patients.163.2. AR inhibitors
JNJ-56021927 (ARN-509, apalutamide; Aragon, San Diego, Cali-
fornia) is a novel second-generation oral AR antagonist that binds
to AR with high afﬁnity and blocks nuclear translocation of AR,
binding of AR to androgen response elements, and recruitment of
coactivators by AR. In a Phase II study with JNJ-56021927, PSA
response (> 50% decline in PSA from baseline after 3 months) was
observed in 91% of nonmetastatic treatment-naïve cases, 88% of
metastatic treatment-naïve cases, and 24% of metastatic post-
abiraterone cases. The Phase III studies SPARTAN (NCT01946204)
and ATLAS (NCT01171898) are evaluating JNJ-56021927 in patients
with nonmetastatic CRPC and high-risk prostate cancer, respec-
tively. Future trials in combination with abiraterone are planned
(NCT01792687).
BAY1841788 (ODM-201; Bayer, Leverkusen, Germany) is another
second-generation ligand-domain binding AR antagonist, which
binds to AR with greater afﬁnity than enzalutamide and does not
accumulate in the central nervous system. In a Phase I and II trial,
known as ARADES, the median time to PSA progression was
72.3 weeks for chemonaïve patients and 20.3 weeks for postchemo
patients.17 A Phase III clinical trial (ARAMIS) is underway.
AZD3514 (AstraZeneca, London, United Kingdom) is an oral drug
that inhibits AR signaling by inhibiting ligand-driven nuclear
translocation of AR and downregulating AR level. In the Phase 1
trial, AZD3514, PSA decline of  50% was observed in 13% of CRPC
patients at a daily dose of 250 mg, and objective soft tissue
response was seen in 17%.18 However, further development of this
agent has been terminated.
EPI-001 (ESSA, Vancouver, Canada) covalently binds to the N-
terminal domain of AR, which is essential for the receptor's tran-
scriptional activity.19 It inhibits transcriptional activity of AR and its
splice variants, and reduces the growth of CRPC in xenografts. EPI-
001 may thus have efﬁcacy in treatment of CRPC progressing after
enzalutamide therapy in which AR variants play a role in tumor
progression. EPI-506 is also an N-terminal domain inhibitor and is a
prodrug of EPI-002.20 Recently, a Phase I and II trial has been
started.4. Cytotoxic chemotherapy and target agents
Docetaxel was approved for metastatic CRPC in 2004 and has
been regarded as the standard treatment in patients with CRPC.
However, the need for novel cytotoxic chemotherapeutic agents
has repeatedly been voiced because of inevitable progression of
disease despite docetaxel treatment. Target agents are broadly used
against various malignancies. In prostate cancer, the role of target
agents was thought to be limited because no well-deﬁned drug-
gable target had been identiﬁed in prostate cancer. However,
because of the safety and efﬁcacy of target agents, increasing efforts
are being put into the development of target agents suitable for
prostate cancer. In this section, the authors will introduce investi-
gational cytotoxic chemotherapeutic drugs and target agents.
4.1. Cytotoxic chemotherapy
Carboplatin (Sagent, Schaumburg, Illinois, United States), a
platinum-based drug, has previously been reported to induce PSA
reduction of  50% in patients with prostate cancer that pro-
gressed after docetaxel chemotherapy.21 Everolimus, an mTOR
inhibitor, in addition to platinum-based chemotherapy, demon-
strated increased antitumor effects and surmounting of resistance
to chemotherapy.22 In this regard, a Phase II study was conducted
to evaluate the efﬁcacy of combination therapy using carboplatin
and everolimus in metastatic prostate cancer patients. In this
study, the combination of carboplatin and everolimus showed no
pharmacokinetic interaction, and the median overall survival was
12.5 months in metastatic CRPC patients who progressed under
docetaxel-based chemotherapy.23
4.2. Target agents
Tasquinimod (Ipsen, Paris, France), a potential anticancer drug,
is an oral quinolone-3-carboxamide derivative. On Phase II evalu-
ation, the median PFS after tasquinimod treatment was signiﬁ-
cantly longer than that for placebo (7.6 months vs. 3.3 months,
P ¼ 0.004).24 In terms of radiographic response, partial response
and stable disease were observed in 7% and 52% of patients after
tasquinimod treatment, respectively. On subgroup analyses, CRPC
patients with bone metastases showed superior PFS after tasqui-
nimod treatment compared with those with visceral or lymph
node-only metastasis. Based on these data, a Phase III trial on
metastatic CRPC and bone metastases was conducted, enrolling
over 1,200 patients (NCT01234311). However, Active Biotech (Lund,
Sweden) reported that tasquinimod failed to prolong survival
(hazard ratio: 1.09; 95% conﬁdence interval: 0.94e1.28) although
the results are not available as of now. Currently, combination trials
with sipuleucel-T (NCT02159950) and cabazitaxel (NCT01513733)
are underway.
Arginine deiminase (ADI), which degrades arginine, reduces
plasma arginine levels and damages tumor cells that lack argini-
nosuccinate synthetase. However, because ADI is highly immuno-
genic, it is conjugated with polyethylene glycol, resulting in the
therapeutic agent pegylated ADI (ADI-PEG 20; Polaris, San Diego,
California, United States), which also has a longer half-life. Auto-
phagy and cell death were observed in prostate cancer cells after
treating themwith ADI-PEG 20 in in vitro studies.25 A recent Phase I
study revealed tolerable toxicity when used in combination with
docetaxel, and a Phase II study was conducted accordingly.26
Alisertib (Takeda Pharmaceutical Company, Osaka, Japan),
previously known as MLN8237, is an Aurora A kinase inhibitor,
which demonstrated antitumor activity in various solid
Prostate Int 4 (2016) 37e4240neoplasms.27 Aurora A kinase is reported to be expressed in 40%
of neuroendocrine prostate cancers, although it is expressed in
only 5% of prostate cancer.28 In addition, after Aurora kinase
inhibitor therapy, complete suppression of neuroendocrine
marker expression was observed. Currently, a Phase II study is
underway (NCT01848067).
OGX-011 (custirsen sodium; Oncogenex, Bothell, Washington,
United States) is an antisense inhibitor for clusterin, which was
reported to restore docetaxel sensitivity in docetaxel-resistant
prostate cancer cells.29 A Phase II study involving metastatic CRPC
patients demonstrated a PFS of 7.3 months after treatment with
OGX-011 and docetaxel, and a PFS of 6.1 months without OGX-011
treatment.30 The overall survival was 23.8 months in the OGX-011
arm and 16.9 months in the placebo arms. A Phase III clinical trial
comparing cabazitaxel/prednisolone in combination with OGX-011
was conducted (NCT01578655).
KPT-330 (Karyopharm, Newton, Massachusetts, United States),
also known as selinexor, is a selective exportin-1 inhibitor with
antitumor effect demonstrated in prostate cancer models.31
Exportin-1-1 is reported to be overexpressed in prostate cancer
and associated with adverse pathologic ﬁndings. A Phase II clinical
trial has started and is recruiting metastatic CRPC patients.
AZD5363 (Otsuka, Tokyo, Japan) is a novel Akt inhibitor reported
to induce autophagy, although apoptosis is not induced.32 Phase II
trials were recently conducted in combination with enzalutamide
(NCT02525068) and docetaxel chemotherapy (NCT02121639).
Cabozantinib (Exelixis, South San Francisco, California, United
States) is an oral multikinase inhibitor for MET and vascular
endothelial growth factor receptor 2. In a Phase II study, a median
PFS of 23.9 weeks was demonstrated in CRPC patients treated
with cabozantinib against a PFS of 5.9 weeks in those treated
with placebo (P < 0.001).33 However, the mechanism leading to
these responses have yet to be fully understood, and a Phase III
clinical trial, performed in 2014, failed to demonstrate a clear
survival beneﬁt.
AMG386 (trebananib; Amgen, Thousand Oaks, California,
United States) is a novel drug that disrupts proliferation of endo-
thelial cells in tumors. A Phase I and II trial is underway to evaluate
the efﬁcacy of the combination of abiraterone and AMG386 in
metastatic CRPC (NCT01553188).
Everolimus (Novartis, Basel, Switzerland) is awell-knownmTOR
inhibitor. In a Phase II study, the combination therapy of bicaluta-
mide and everolimus was shown to be effective in CRPC patients
who were not previously treated using bicalutamide.34 Among 24
patients enrolled in the study, 18 (75%) showed a PSA response. A
Phase II study evaluating everolimus monotherapy is underway
(NCT00976755).
TKI258 (dovitinib; Novartis, Basel, Switzerland), a ﬁbroblast
growth factor receptor tyrosine kinase inhibitor, has been shown to
inhibit bonemetastasis of prostate cancer.35 A Phase II trial is on the
way (NCT01741116).5. Vaccines, immunotherapy, and gene-based therapy
Despite advances in treatment of prostate cancer, curative
therapy is not yet available for CRPC. Novel therapeutic options
have thus been sought, and vaccines, immunotherapy, and gene-
based therapy are considered to be attractive candidates in this
respect. Up to now, sipuleucel-T is the only such treatment
approved by the Food and Drug Administration. In this section, the
authors will brieﬂy introduce investigational vaccines, immuno-
therapy, and gene-based therapy for CRPC.5.1. Vaccine
GX301 (Genovax, London, United Kingdom) is a dual-adjuvant
telomerase vaccine. GX301 is reported to be safe and highly
immunogenic in patients with prostate cancer.36 A Phase II ran-
domized trial is underway (NCT02293707).
Prostvac (Barvarian Nordic, Martinsried, Germany) is a vector-
based therapeutic cancer vaccine. A Phase II study reported that
prostvac was well tolerated and it improved overall survival
compared with control vectors (25.1 months vs. 16.6 months) in
patients with minimally symptomatic CRPC.37 However, another
Phase II study, which evaluated the effect of the combination of
docetaxel and prostvac, failed to show improvements in overall
survival; this lack of positive results may be due to limited accrual
of aptients.38 Investigation on the relative efﬁcacy of simultaneous
versus sequential docetaxel þ prostvac is currently ongoing
(NCT02649855).
DCVAC is an autologous dendritic cell-based vaccine. In a Phase I
and II trial, combination chemoimmunotherapy with DCVAC and
docetaxel resulted in longer than expected survival (19 months vs.
11.8 months) without signiﬁcant complications.39 A Phase III study,
evaluating the merits of DCVAC when added to standard chemo-
therapy, is due to commence (NCT02111577).5.2. Immunotherapy
Ipilimumab (yervoy; Bristol-Myers Squibb, New York, United
States) is a monoclonal antibody that blocks the activity of CTLA-4
(cytotoxic T-lymphocyte-associated protein 4) and was approved
by the Food and Drug Administration for the treatment of mela-
noma in 2011. As preclinical and clinical studies suggested that
radiotherapy might activate the immune system in patients with
prostate cancer,40,41 a Phase III trial of ipilimumab in addition to
radiotherapy for metastatic CRPC patients was initiated. However,
this Phase III study did not show any improvement in overall sur-
vival (11.2 months vs. 10.0 months, P ¼ 0.053) after radiotherapy
followed by ipilimumab, compared with radiotherapy followed by
placebo.42 Currently, combination trials with abiraterone
(NCT01688492), ADT (NCT01498978), sipuleucel-T (NCT01804465),
and prostvac (NCT02506114) are underway.
177Lu-J591 (ATLAB, Nantes, France), a humanized monoclonal
antibody, was primarily developed in a radiolabeled form for PET,
binding to the extracellular domain of prostate-speciﬁc membrane
antigen (PSMA). After binding to PSMA, the 177Lu-J591ePSMA
complex undergoes endocytosis and is accumulated in prostate
cancer cells. In this regard, 177Lu-J591J591 is considered to be a
potential carrier for cytotoxic drug conjugates to maximize thera-
peutic effectiveness43 and a promising agent for radio-
immunotherapy. Currently, a Phase 2 clinical trial is in the process
of patient recruitment (NCT00859781).5.3. Gene-based therapy
Olaparib (AstraZeneca, London, United Kingdom), recently
approved for treating ovarian cancer with BRCA1/2 mutations, is a
poly-ADT-ribose polymerase inhibitor. Poly-ADT-ribose polymer-
ase is involved in the DNA repair process, and genomic aberrations
observed in CRPC are thought to confer sensitivity to poly-ADT-
ribose polymerase inhibitors. In recent studies, olaparib showed a
considerable response rate of 33% in post-docetaxel prostate cancer
patients with defects in DNA repair genes,44 and a Phase II trial has
commenced (NCT01682772).
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Treatment regimens for prostate cancer have undergone recent
changes due to the introduction of new drugs such as docetaxel,
enzalutamide, abiraterone acetate, cabazitaxel, radium-223, and
sipuleucel-T. More novel agents are undergoing evaluation or
awaiting approval to address their shortcomings, and clinicians
should be aware of recent developments in order to provide
optimal care to patients with prostate cancer, especially CRPC.Conﬂicts of interest
There is no ﬁnancial disclosure from any authors.References
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